^
    5d
    DUAL-NK-PDAC: Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Beijing Biotech
    New P1/2 trial
    |
    CLDN18 (Claudin 18) • MSLN (Mesothelin)
    |
    CLDN18.2 positive
    |
    cyclophosphamide • fludarabine IV
    1m
    MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    MUC1 (Mucin 1)
    |
    Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
    1m
    Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (clinicaltrials.gov)
    P2, N=110, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    Undisclosed MUC1 peptide-poly-ICLC adjuvant vaccine
    2ms
    Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov)
    P1, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    Leukine (sargramostim) • Panvac-VF (falimarev/inalimarev)
    2ms
    Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 Trial. (PubMed, NPJ Breast Cancer)
    ABCSG-34 randomized 400 patients to chemotherapy or endocrine therapy, with or without the MUC1 vaccine tecemotide...While ctDNA clearance may reflect treatment efficacy, further validation in larger trials is needed. Ongoing studies will determine the role of ctDNA in guiding therapy and monitoring MRD.
    Journal • Circulating tumor DNA
    |
    MUC1 (Mucin 1)
    |
    Stimuvax (tecemotide)
    2ms
    A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=33, Completed, Beth Israel Deaconess Medical Center | Active, not recruiting --> Completed
    Trial completion
    |
    decitabine • GO-203-2c
    4ms
    BGB-B3227-101: A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=35, Terminated, BeiGene | N=75 --> 35 | Trial completion date: Jan 2027 --> Dec 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Dec 2025; Sponsor Decision
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)
    7ms
    Tackling cancer heterogeneity with systemically delivered oncolytic adenoviruses transcriptionally targeted with hybrid promoters. (PubMed, Mol Ther Oncol)
    Systemic administration of AR2015 significantly inhibited the growth of CRC-derived liver metastases expressing A33 and vWA2, with further therapeutic benefit observed in combination with oxaliplatin. These findings provide proof of concept for addressing tumor heterogeneity through transcriptionally targeted OAds driven by hTSPs.
    Journal
    |
    VWA2 (Von Willebrand Factor A Domain Containing 2)
    |
    oxaliplatin • BrevaRex (AR20.5)
    8ms
    TITER: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker
    |
    Keytruda (pembrolizumab) • irinotecan
    8ms
    Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. (PubMed, ESMO Open)
    PDC∗lung01 was immunogenic and had a manageable safety profile in all cohorts and met the predefined clinical objectives when combined with anti-PD-1 in metastatic NSCLC. Median PFS was positively correlated with antigen-specific T-cell expansions.
    P1/2 data • Journal
    |
    PD-L1 (Programmed death ligand 1) • MUC1 (Mucin 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CTAG1B (Cancer/testis antigen 1B) • MAGEA4 (Melanoma antigen family A, 4)
    |
    PDC*lung
    9ms
    Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. (PubMed, Cells)
    T-cell vaccines, designed to activate cytotoxic CD8+ T-cell responses, have been tested across multiple platforms, including peptide-based (MAGE-A3), viral vector (TG4010/MUC1), and mRNA (CV9201/92) formulations. Recent advances include cytokine-enhanced, memory-like NK cells to overcome immunosuppression and "off-the-shelf" products for broader clinical use. Together, these cellular immunotherapies represent a versatile and evolving frontier in NSCLC treatment, with ongoing research optimizing combinations, delivery platforms, and patient selection to maximize therapeutic benefit.
    Review • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • MUC1 (Mucin 1)
    |
    mesmulogene ancovacivec (TG4010)
    9ms
    TITER: M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=77, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1 trial • IO biomarker
    |
    Keytruda (pembrolizumab) • irinotecan